Human Pluripotent Stem Cells for the Treatment of Type 1 Diabetes | Recording-Human Pluripotent Stem Cells for the Treatment of Type 1 Diabetes

Video Transcription

Video Summary

Dr. Doug Melton and Dr. Shu-Bing Chen presented on the use of human pluripotent stem cells for the treatment of type 1 diabetes. Dr. Melton discussed the protocol for manufacturing stem cell-derived islets, as well as the results of a clinical trial in which patients received the islets along with non-steroidal immunosuppressants. He also highlighted the need to improve the protocol for manufacturing and to find ways to eliminate the need for systemic immune suppression. Dr. Chen discussed the use of stem cell models for studying the genetic and environmental factors that contribute to diabetes progression. She presented examples of gene knockouts and SNP knock-ins that were performed using CRISPR-based gene editing. She also described the establishment of a diabetes-in-a-dish model for studying the effects of environmental factors on beta cell function and survival. Additionally, Dr. Chen discussed the development of a drug screening platform to identify small molecules that can rescue the phenotype of knockout cell lines. Overall, both presenters emphasized the potential of human pluripotent stem cells for advancing the understanding and treatment of type 1 diabetes.

Keywords

human pluripotent stem cells

type 1 diabetes

stem cell-derived islets

clinical trial

immunosuppressants

gene editing

diabetes progression

environmental factors

drug screening platform